Pay in 4 interest-free payments of $6.84 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Data availability The datasets generated and analyzed during this study are included in the Supplementary files
Dose reduction or slower titration schedules can help manage symptoms whilst maintaining glycaemic control
What researchers study it for: GLP-1 receptor pharmacology how the receptor is activated and signals Blood-sugar and metabolic models a core area of study Comparative research a benchmark against dual/triple agonists Appetite-signaling pathways how the GLP-1 system is wired A benchmark molecule is only useful if it is exactly what the label claims that is the whole point of a reference compound
Recognition of Healthcare Burden: There is an ever-increasing awareness that treating obesity results in meaningful improvement in cardiovascular outcomes and lowers the risk of developing multiple related cardiometabolic diseases including Type 2 Diabetes Mellitus (T2DM), chronic kidney disease (CKD), heart failure, fatty liver or MASH, obstructive sleep apnea (OSA), and peripheral arterial disease (PAD), moving the needle beyond aesthetics and towards total health improvement
US$ 25.26
US$ 21.62
US$ 25.74
US$ 22.54
US$ 23.73
US$ 26.34
